Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.89 |
| ▸ | CA7 | P43166 | 6/20 | 0.89 |
| ▸ | CA9 | Q16790 | 6/20 | 0.89 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.89 |
| ▸ | CA1 | P00915 | 5/20 | 0.89 |
| ▸ | CA2 | P00918 | 4/20 | 0.89 |
| ▸ | TYR | P14679 | 3/20 | 0.89 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.61 |
| ▸ | AKR1B10 | O60218 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL404485 | 1.00 | CA12 (0.89) | CA12CA7CA9CA14CA1 | |
| Methyl P-Hydroxycinnamate SCHEMBL895938 | 0.94 | CA12 (1.00) | CA12CA7CA9CA14CA1 | |
| Methyl P-Hydroxycinnamate SCHEMBL28386655 | 0.94 | CA12 (1.00) | CA12CA7CA9CA14CA1 | |
| Methyl P-Hydroxycinnamate SCHEMBL547438 | 0.94 | CA12 (1.00) | CA12CA7CA9CA14CA1 | |
| Methyl P-Hydroxycinnamate SCHEMBL30463538 | 0.94 | CA12 (1.00) | CA12CA7CA9CA14CA1 | |
| Methyl P-Hydroxycinnamate SCHEMBL28876782 | 0.91 | CA12 (0.93) | CA12CA7CA9CA14CA1 | |
| SCHEMBL15014368 | 0.91 | CA12 (0.73) | CA12CA7CA9CA14CA1 | |
| SCHEMBL12909029 | 0.87 | CA2 (0.68) | CA12CA7CA9CA14CA1 | |
| SCHEMBL71224 | 0.87 | CA12 (0.84) | CA12CA7CA9CA14CA1 | |
| SCHEMBL5057418 | 0.87 | CA12 (0.84) | CA12CA7CA9CA14CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100330200-A1 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-12-30 | — | — | US | claimed |
| EP-2101820-A2 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2009-09-23 | — | — | EP | claimed |
| WO-2008077772-A2 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA (IT) | 2008-07-03 | — | — | WO | claimed |
| US-8535769-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, and oriented film | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-09-17 | — | — | US | disclosed |
| US-8535769-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, and oriented film | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-09-17 | — | — | US | disclosed |
| EP-2479170-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, AND ORIENTED FILM | Nissan Chemical Industries, Ltd. (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120172560-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, AND ORIENTED FILM | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20120172560-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, AND ORIENTED FILM | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| US-8101793-B2 | Anticarcinogenic and antimetastasis agents; leukemia or Hodgkin's disease. | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-01-24 | — | — | US | disclosed |
| US-8101793-B2 | Anticarcinogenic and antimetastasis agents; leukemia or Hodgkin's disease. | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-01-24 | — | — | US | disclosed |
| US-20100330200-A1 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-12-30 | — | — | US | disclosed |
| US-20080021088-A1 | Retinoid Derivatives With Antiangiogenic, Antitumoral And Proapoptotic Activities | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-01-24 | — | — | US | disclosed |
| US-20080021088-A1 | Retinoid Derivatives With Antiangiogenic, Antitumoral And Proapoptotic Activities | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-01-24 | — | — | US | disclosed |
| CN-1279014-C | Retinoid derivatives having antiangiogenic, antitumor and pro-apoptotic activities | SIGMA TAU IND FARMACEUTI (IT) | 2006-10-11 | — | — | CN | disclosed |
| CN-1203089-C | New compound | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-05-25 | — | — | CN | disclosed |
| US-20040235757-A1 | Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-11-25 | — | — | US | disclosed |
| CN-1537094-A | Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities | ϣ��������ҩ��ҵ��˾ | 2004-10-13 | — | — | CN | disclosed |
| EP-1412317-A1 | RETINOID DERIVATIVES WITH ANTIANGIOGENIC, ANTITUMOR AND PROAPOPTOTIC ACTIVITIES | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003011808-A1 | RETINOID DERIVATIVES WITH ANTIANGIOGENIC, ANTITUMORAL AND PROAPOPTOTIC ACTIVITIES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-02-13 | — | — | WO | disclosed |
| CN-1168675-A | Novel compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-12-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021088-A1 | Retinoid Derivatives With Antiangiogenic, Antitumoral And Proapoptotic Activities | RARA, RARB, RXRA | CA12 2330/4885CA7 1539/4885CA9 1800/4885 |
| US-20040235757-A1 | Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities | RARA, RARB, RARG | CA12 2450/4885CA7 1692/4885CA9 1917/4885 |
| US-20120172560-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, AND ORIENTED FILM | CRY1, NAP1L1, LAS1L | CA12 982/4885CA7 1480/4885CA9 704/4885 |
| US-20100330200-A1 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | CXCR4, RARA, CXCL12 | CA12 311/4885CA7 480/4885CA9 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.